AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8091240 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, ifosfamide, mitolactol, and vincristine
Number of subjects: 0
Study 8091240 — intervention group
Group type: EXPERIMENTAL
Intervention: New platinum-based regimens
Number of subjects: 0
Study 3292601 — intervention group
Group type: EXPERIMENTAL
Intervention: Superactivated charcoal (20 g twice daily)
Number of subjects: 6
Study 3292601 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (8 g twice daily)
Number of subjects: 6
Study 31845435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive cement
Number of subjects: 50
Study 31845435 — intervention group
Group type: COMPARATOR
Intervention: Packable glass ionomer
Number of subjects: 50
Study 30912806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GH/GnRHa therapy
Number of subjects: 192
Study 30912806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepubertal status at onset of GH treatment
Number of subjects: 192
Study 30912806 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 192
Study 28830024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive exercise therapy (CET) in addition to cognitive-behavioral therapy (CBT) and graded exercise therapy (GET)
Number of subjects: 72
Study 28830024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive exercise therapy (CET)
Number of subjects: 72
Study 28830024 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) and graded exercise therapy (GET) alone
Number of subjects: 72
Study 25638341 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized hormone adjustment (estrogen, progesterone, and luteinizing hormones)
Number of subjects: 171
Study 24344178 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressed participants
Number of subjects: 0
Study 24344178 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 21522037 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab (15 mg/kg, five monthly doses)
Number of subjects: 1236
Study 21522037 — intervention group
Group type: COMPARATOR
Intervention: Palivizumab (15 mg/kg, five monthly doses)
Number of subjects: 1236
Study 21522037 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 1236
Study 21522037 — intervention group
Group type: COMPARATOR
Intervention: Palivizumab
Number of subjects: 1236
Study 19883270 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactulose
Number of subjects: 27
Study 19883270 — intervention group
Group type: COMPARATOR
Intervention: 10 g glucose (placebo)
Number of subjects: 27
Study 16534469 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 75
Study 16534469 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 75
Study 16534469 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no therapy)
Number of subjects: 75
Study 12813203 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-methylene diphosphonate (99mTc-MDP)
Number of subjects: 70
Study 11571823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 232
Study 11571823 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 232
Study 9558860 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia
Number of subjects: 32
Study 9558860 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia
Number of subjects: 32
Study 7528560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime) (N = 20)
Number of subjects: 40
Study 7528560 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group (N = 20)
Number of subjects: 40
Study 2921600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 50 mg/day
Number of subjects: 0
Study 2921600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg/day
Number of subjects: 0
Study 2921600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 200 mg/day
Number of subjects: 0
Study 2921600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31863843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium warnings
Number of subjects: 498
Study 30986531 — intervention group
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular VNS (tVNS)
Number of subjects: 58
Study 30986531 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 58
Study 28097332 — intervention group
Group type: COMPARATOR
Intervention: Postoperative incentive spirometry (IS)
Number of subjects: 224
Study 25446610 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with capecitabine (1200 mg/m²/d Monday‐Friday) plus irinotecan (50 mg/m²/wk × 4)
Number of subjects: 104
Study 25446610 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with capecitabine (1650 mg/m²/d Monday‐Friday) plus oxaliplatin (50 mg/m²/wk × 5)
Number of subjects: 104
Study 23691062 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis therapy (ATT) with corticosteroids for IRIS treatment
Number of subjects: 57
Study 23691062 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma IL-6 and CRP levels
Number of subjects: 57
Study 21856268 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐NBI
Number of subjects: 353
Study 21856268 — intervention group
Group type: COMPARATOR
Intervention: C‐WLI
Number of subjects: 353
Study 21856268 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐NBI with C‐WLI
Number of subjects: 353
Study 19293593 — intervention group
Group type: EXPERIMENTAL
Intervention: RET‐Y measurement in patients with absolute iron deficiency
Number of subjects: 289
Study 19293593 — intervention group
Group type: EXPERIMENTAL
Intervention: RET‐Y measurement in patients with functional iron deficiency
Number of subjects: 289
Study 19293593 — intervention group
Group type: EXPERIMENTAL
Intervention: RET‐Y measurement in EPO‐independent patients
Number of subjects: 289
Study 19293593 — intervention group
Group type: EXPERIMENTAL
Intervention: RET‐Y levels comparison to normal population
Number of subjects: 289
Study 19293593 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of RET‐Y levels
Number of subjects: 289
Study 17412546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05mmol/kg gadodiamide
Number of subjects: 273
Study 17412546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mmol/kg gadodiamide
Number of subjects: 273
Study 17412546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2mmol/kg gadodiamide
Number of subjects: 273
Study 17412546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01mmol/kg gadodiamide
Number of subjects: 273
Study 17412546 — intervention group
Group type: COMPARATOR
Intervention: All doses compared to 0.01mmol/kg
Number of subjects: 273
Study 14769684 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg)
Number of subjects: 16608
Study 14769684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 11124753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium-tagged yogurt (500 mL) for 6 weeks
Number of subjects: 90
Study 11124753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium supplement (250 micromol/d) for 13 days
Number of subjects: 90
Study 11124753 — intervention group
Group type: EXPERIMENTAL
Intervention: Half the dose (125 micromol lithium/d) taken on each of 2 days
Number of subjects: 90
Study 9188873 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® cream
Number of subjects: 12
Study 9188873 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA® patch
Number of subjects: 12
Study 8453559 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interferon alfa‐2a and IL‐2 at a dose of 7.5 million units (MU)/m2 of interferon alfa‐2a and 1.5 MU/m2 of IL‐2, administered three and five times weekly for 4 weeks
Number of subjects: 33
Study 2943106 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal luteal phase
Number of subjects: 28
Study 2943106 — intervention group
Group type: COMPARATOR
Intervention: Normal follicular phase
Number of subjects: 28
Study 2943106 — intervention group
Group type: COMPARATOR
Intervention: Hyperandrogenism
Number of subjects: 28
Study 2943106 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (150 mg trimestrially)
Number of subjects: 28
Study 2943106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl-oestradiol (1 mg daily for 5 days)
Number of subjects: 28
Study 2943106 — intervention group
Group type: EXPERIMENTAL
Intervention: Days +4 to +9 of menstrual cycle (luteal phase)
Number of subjects: 28
Study 29337026 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 4 mg group
Number of subjects: 76
Study 29337026 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 8 mg group
Number of subjects: 76
Study 29337026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 27072941 — intervention group
Group type: EXPERIMENTAL
Intervention: 38‐h communication skills training program for multidisciplinary radiotherapy teams
Number of subjects: 198
Study 27072941 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 198
Study 24470256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile cue presented to the left or right hand with hands aligned with inner visual target locations.
Number of subjects: 0
Study 24470256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile cue presented to the left or right hand with hands aligned with outer visual target locations.
Number of subjects: 0
Study 24470256 — intervention group
Group type: EXPERIMENTAL
Intervention: Unseen posture changes with inner and outer target eccentricities of 10º and 86º.
Number of subjects: 0
Study 24470256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands completely covered during the experiment.
Number of subjects: 0
Study 24470256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands in view during the experiment.
Number of subjects: 0
Study 22353915 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (Group II) - guardians received a pamphlet about how to help a child cooperate with the dentist during dental treatment.
Number of subjects: 235
Study 22353915 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I) - guardians received a pamphlet about how to clean children's teeth.
Number of subjects: 235
Study 20198451 — intervention group
Group type: COMPARATOR
Intervention: 15 ml/kg total body weight (TBW) of IV crystalloid solution (Group A)
Number of subjects: 100
Study 20198451 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml/kg total body weight (TBW) of IV crystalloid solution (Group B)
Number of subjects: 100
Study 18668692 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of dexamethasone (1 mg/kg)
Number of subjects: 125
Study 18668692 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of dexamethasone (0.15 mg/kg for 4 days)
Number of subjects: 125
Study 18668692 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of dexamethasone
Number of subjects: 125
Study 18668692 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of dexamethasone
Number of subjects: 125
Study 15982131 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D relatable displays
Number of subjects: 0
Study 15982131 — intervention group
Group type: COMPARATOR
Intervention: 3-D nonrelatable displays
Number of subjects: 0
Study 12584784 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangqian granule (JQG)
Number of subjects: 80
Study 12584784 — intervention group
Group type: COMPARATOR
Intervention: Ritalin (Control)
Number of subjects: 80
Study 10614835 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (initial dose of 2.0 g followed by a constant infusion at 20 mg/min)
Number of subjects: 27
Study 10614835 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PTCA without vitamin C
Number of subjects: 27
Study 10614835 — intervention group
Group type: COMPARATOR
Intervention: Elective PTCA in stable effort angina (Control Group)
Number of subjects: 27
Study 7627244 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 30 mg/day
Number of subjects: 188
Study 7627244 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 180 mg/day
Number of subjects: 188
Study 7627244 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day
Number of subjects: 188
Study 7627244 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (Placebo)
Number of subjects: 188
Study 1512604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (50 mg daily) and dipyridamole (400 mg daily)
Number of subjects: 0
Study 1512604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6390998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin in combination with dihydroergotamine
Number of subjects: 200
Study 6390998 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin alone
Number of subjects: 200
Study 30328246 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 100 mg/day for 8 weeks
Number of subjects: 60
Study 30328246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29981086 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 home visits with a health educator, emails, and mailed incentives (4HV)
Number of subjects: 44
Study 29981086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 home visits with a health educator, emails, and mailed incentives (2HV)
Number of subjects: 44
Study 29981086 — intervention group
Group type: COMPARATOR
Intervention: General health advice through emails (control)
Number of subjects: 44
Study 26207956 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D video training
Number of subjects: 0
Study 26207956 — intervention group
Group type: COMPARATOR
Intervention: 2D video training
Number of subjects: 0
Study 26207956 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26207956 — intervention group
Group type: COMPARATOR
Intervention: Traditional tactic board training
Number of subjects: 0
Study 24434503 — intervention group
Group type: EXPERIMENTAL
Intervention: Samatasvir 25-100mg per day for 3 days
Number of subjects: 64
Study 24434503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22278874 — intervention group
Group type: EXPERIMENTAL
Intervention: Antistick phospholipid solution (Electro Lube)
Number of subjects: 61
Study 22278874 — intervention group
Group type: COMPARATOR
Intervention: Control (no antistick solution)
Number of subjects: 61
Study 21084043 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiflo ICON 400 µg tablets
Number of subjects: 32
Study 21084043 — intervention group
Group type: COMPARATOR
Intervention: Flomaxtra XL 400 µg tablets
Number of subjects: 32
Study 18540781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg
Number of subjects: 24
Study 18540781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5.0 mg
Number of subjects: 24
Study 18540781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15906662 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.7 mg/kg/d) plus rifampin (600 mg/d) for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Number of subjects: 40
Study 15906662 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.7 mg/kg/d) alone for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Number of subjects: 40
Study 12571861 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (placebo-controlled study)
Number of subjects: 67
Study 12571861 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic scoring method
Number of subjects: 67
Study 10558970 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially enteric‐coated preparation of bovine immunoglobulins
Number of subjects: 20
Study 10558970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8549868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 44
Study 8549868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 44
Study 8549868 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril and Amlodipine
Number of subjects: 44
Study 1846057 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (10 to 40 mg)
Number of subjects: 144
Study 1846057 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg)
Number of subjects: 144
Study 6354602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol (60 or 30 mg)
Number of subjects: 54
Study 6354602 — intervention group
Group type: COMPARATOR
Intervention: Codeine (60 mg)
Number of subjects: 54
Study 6354602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31837947 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (LV-HIIT)
Number of subjects: 50
Study 31837947 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise training (MICET)
Number of subjects: 50
Study 31837947 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 30744672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SIT)
Number of subjects: 216
Study 30744672 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 216
Study 28527421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine HCl 3.2mg daily in four divided doses
Number of subjects: 264
Study 28527421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 28527421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 264
Study 26400476 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 55
Study 26400476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24090266 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of ramelteon (melatonin agonist)
Number of subjects: 8
Study 24090266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22461887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting in a 'straight' position
Number of subjects: 25
Study 22461887 — intervention group
Group type: COMPARATOR
Intervention: Sitting in a 'bent' position
Number of subjects: 25
Study 19623858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyman NTCP model
Number of subjects: 0
Study 19623858 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical volume NTCP model
Number of subjects: 0
Study 19623858 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative seriality NTCP model
Number of subjects: 0
Study 19623858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Lung Dose (MLD)
Number of subjects: 0
Study 19623858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volumes irradiated at 10Gy (V10)
Number of subjects: 0
Study 19623858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volumes irradiated at 20Gy (V20)
Number of subjects: 0
Study 17298463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial washing before forceps biopsy (pre-biopsy)
Number of subjects: 207
Study 17298463 — intervention group
Group type: COMPARATOR
Intervention: Bronchial washing after forceps biopsy (post-biopsy)
Number of subjects: 207
Study 17298463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial washing (both groups)
Number of subjects: 207
Study 15086698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 21
Study 15086698 — intervention group
Group type: COMPARATOR
Intervention: Standard urticaria therapies (corticosteroids, H2-antihistamines, H1-antihistamines, doxepin)
Number of subjects: 21
Study 11895352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Number of subjects: 0
Study 11895352 — intervention group
Group type: COMPARATOR
Intervention: No nerve conduction studies
Number of subjects: 0
Study 9793619 — intervention group
Group type: EXPERIMENTAL
Intervention: MDPI (100 micrograms of salbutamol)
Number of subjects: 36
Study 9793619 — intervention group
Group type: COMPARATOR
Intervention: pMDI + S (100 micrograms of salbutamol)
Number of subjects: 36
Study 7714461 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 or 10 mg daily for 6 weeks)
Number of subjects: 68
Study 7714461 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 68
Study 1955055 — intervention group
Group type: EXPERIMENTAL
Intervention: Early trabeculectomy
Number of subjects: 104
Study 1955055 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 104
Study 7009090 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent adhesive drape
Number of subjects: 90
Study 7009090 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 90
Study 31290481 — intervention group
Group type: EXPERIMENTAL
Intervention: ANIN RS I (risk score for all-cause mortality)
Number of subjects: 1064
Study 31290481 — intervention group
Group type: EXPERIMENTAL
Intervention: ANIN RS II (risk score for cardiovascular mortality)
Number of subjects: 1064
Study 27937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via MDPI 50, 100, 200, or 400 mcg twice daily for 12 weeks
Number of subjects: 640
Study 27937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via MDPI
Number of subjects: 640
Study 27937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via MDPI and Fp DPI
Number of subjects: 640
Study 27937064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via DPI 250 mcg
Number of subjects: 640
Study 27937064 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 640
Study 25605838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib-capecitabine
Number of subjects: 540
Study 25605838 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab-capecitabine
Number of subjects: 540
Study 24923372 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg)
Number of subjects: 60
Study 24923372 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone sodium (5 mg/kg)
Number of subjects: 60